Compass Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

CMPX$0.84+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets (Unaudited)

Condensed Consolidated Balance Sheets

(In thousands, except par value)

	June 30, 2026 (unaudited)	December 31, 2025 (Note 1)
Assets
Current assets:
Cash and cash equivalents	$35,453	$30,643
Marketable securities	144,426	178,263
Prepaid expenses and other current assets	1,011	913
Total current assets	180,890	209,819
Property and equipment, net	324	102
Operating lease, right-of-use ("ROU") asset	8,391	9,099
Restricted cash	568	568
Total assets	$190,173	$219,588
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$2,906	$1,585
Accrued expenses	11,585	11,383
Operating lease obligations, current portion	1,637	1,000
Total current liabilities	16,128	13,968
Operating lease obligations, long-term portion	7,996	8,829
Total liabilities	24,124	22,797
Commitments and contingencies (Note 7)
Stockholders' equity:
Common stock, $0.0001 par value: 300,000 shares authorized; 180,088 and 178,324 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	18	18
Additional paid-in-capital	640,925	627,665
Accumulated other comprehensive income (loss)	(251)	280
Accumulated deficit	(474,643)	(431,172)
Total stockholders' equity	166,049	196,791
Total liabilities and stockholders' equity	$190,173	$219,588

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.